Literature DB >> 18092143

Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade.

Shinji Urakami1, Hiroaki Shiina, Masahiro Sumura, Satoshi Honda, Koji Wake, Takeo Hiraoka, Shogo Inoue, Noriyoshi Ishikawa, Mikio Igawa.   

Abstract

Metastatic prostate cancer (PC) is incurable by androgen deprivation therapy alone, due to the presence of androgen-independent/supersensitive cells in hormone-naive PC. A 67-year-old man was diagnosed with PC (Gleason score, 5 + 4) with multiple bone metastases. He was treated by chemohormonal therapy with cisplatin and estramustine phosphate (EMP) followed by maximal androgen blockade, and showed a complete response. As of the time of writing, no clinical or prostate-specific antigen recurrence has been observed for over 15 years, despite cessation of the treatment. This is the first report to indicate a possible cure of metastatic PC by chemohormonal therapy combined with appropriate anti-tumor drugs targeted to both androgen-independent and -dependent clones before the hormone-refractory state.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18092143     DOI: 10.1007/s11255-007-9301-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

1.  Mechanisms of androgen-refractory prostate cancer.

Authors:  Jose D Debes; Donald J Tindall
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

2.  Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.

Authors:  Nobuyuki Kikuno; Shinji Urakami; Shigeru Nakamura; Takeo Hiraoka; Taijyu Hyuga; Naoko Arichi; Kouji Wake; Masahiro Sumura; Tatsuaki Yoneda; Hirofumi Kishi; Kazushi Shigeno; Hiroaki Shiina; Mikio Igawa
Journal:  Eur Urol       Date:  2006-12-26       Impact factor: 20.096

Review 3.  Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

Authors:  William K Oh; Miah-Hiang Tay; Jiaoti Huang
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

4.  Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.

Authors:  Adam S Kibel; Eli Rosenbaum; Michael W Kattan; Joel Picus; Robert Dreicer; Eric A Klein; Gurkamal S Chatta; Joel B Nelson; Robert S DiPaola; Bruce J Roth; Michael S Cookson; George Wilding; David F Jarrard; Tomasz M Beer; Christopher W Ryan; Daniel P Petrylak; Mitchell C Benson; Alan W Partin; Elizabeth Garrett-Mayer; Mario A Eisenberger
Journal:  J Urol       Date:  2007-05       Impact factor: 7.450

5.  Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.

Authors:  J T Isaacs
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

6.  Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.

Authors:  Mary-Ellen Taplin; Wanling Xie; Glenn J Bubley; Marc S Ernstoff; William Walsh; Daniel E Morganstern; Meredith M Regan
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

7.  Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.

Authors:  Tomaso Prayer-Galetti; Emilio Sacco; Francesco Pagano; Marina Gardiman; Antonio Cisternino; Giovanni Betto; Paola Sperandio; Paolo Sperandio
Journal:  BJU Int       Date:  2007-03-12       Impact factor: 5.588

8.  Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?

Authors:  Fernand Labrie; Bernard Candas; Jose-Luis Gomez; Leonello Cusan
Journal:  Urology       Date:  2002-07       Impact factor: 2.649

9.  Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.

Authors:  Shinji Urakami; Mikio Igawa; Nobuyuki Kikuno; Tateki Yoshino; Hirofumi Kishi; Kazushi Shigeno; Hiroaki Shiina
Journal:  J Urol       Date:  2002-12       Impact factor: 7.450

10.  Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.

Authors:  Masanori Noguchi; Shinshi Noda; Masaki Yoshida; Shoichi Ueda; Taizo Shiraishi; Kyogo Itoh
Journal:  Int J Urol       Date:  2004-02       Impact factor: 3.369

  10 in total
  3 in total

Review 1.  Does chemotherapy have a role before hormone-resistant disease develops?

Authors:  James P Dean; Celestia S Higano
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

2.  Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.

Authors:  Yi Lu; Xiongwen Zhang; Ben Beheshti; Jun Zhang
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

3.  Mitochondrial dysfunction mediated apoptosis of HT-29 cells through CS-PAC-AgNPs and investigation of genotoxic effects in zebra (Danio rerio) fish model for drug delivery.

Authors:  Mani Suganya; Balasubramanian Mythili Gnanamangai; Chandramohan Govindasamy; Mohamed Farouk Elsadek; Arivalagan Pugazhendhi; Veeramani Chinnadurai; Arokiyaraj Selvaraj; Balasubramani Ravindran; Soon Woong Chang; Ponnusamy Ponmurugan
Journal:  Saudi J Biol Sci       Date:  2019-03-20       Impact factor: 4.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.